Category Archives: TRIPS&IP rights

Facebook Twitter Whatsapp Intellectual Property for the Twenty-First-Century Economy

Source: Project Syndicate Developing countries are increasingly pushing back against the intellectual property regime foisted on them by the advanced economies over the last 30 years. They are right to do so, because what matters is not only the production … Continue reading

Posted in IPR, Patent, TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment

Section 301: US investigates allegations of forced technology transfers to China

Source: EastAsia Forum Authors: Zhiyao (Lucy) Lu and Gary Clyde Hufbauer, Peterson Institute for International Economics On 18 August 2017, the Trump administration invoked Section 301 of the Trade Act of 1974 to launch an investigation into alleged Chinese violations of intellectual … Continue reading

Posted in Seizures, Special 301 report, Uncategorized, WTO | Leave a comment

Malaysian CL on Hep C drug reignites discussion in India

Source: The Hindu BusinessLine MUMBAI, OCTOBER 9:   Last month, Malaysia issued a compulsory licence (CL) on multinational drugmaker Gilead’s Hepatitis C drug Sofosbuvir for government use. This government action aimed at improving access to the drug in Malaysia has in fact … Continue reading

Posted in Compulsory Licensing, Hepatitis C, TRIPS flexibilities, Uncategorized | Leave a comment

US needs to push range of economic issues with India: Kenneth Juster

Source: The Economic Times WASHINGTON: The US must push a range of economic issues with India, including intellectual property, standard and non-tariff barriers, President Donald Trump’s nominee to be the next envoy to India has told lawmakers. Underlining that there … Continue reading

Posted in Compulsory Licensing, IPR, Uncategorized | Leave a comment

DNDi welcomes Malaysia’s move to secure access to more affordable treatments for hepatitis C

[Kuala Lumpur, Geneva – 20 September 2017] Malaysia has issued a “government use” licence enabling access to more affordable versions of an expensive and patented medicine to treat hepatitis C. This landmark decision should help the more than 400,000 people living with … Continue reading

Posted in Compulsory Licensing, Hepatitis C, Uncategorized | Leave a comment

Seven Decades of Grappling With Intellectual Property Issues in India

Create, Copy, Disrupt: India’s Intellectual Property Dilemmas is well-researched and easy to read, especially for a non-legal audience. By Jayashree Watal, The Wire The book Create, Copy, Disrupt: India’s Intellectual Property Dilemmas (OUP, 2017) is a serious effort by two legal scholars, Prashant … Continue reading

Posted in IPR, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

India grants Pfizer patent for pneumonia vaccine

Source: Live Mint India has granted Pfizer a patent for Prevnar 13 pneumonia vaccine, in spite of opposition from the heath group Médecins Sans Frontières (MSF) New Delhi: India has granted US pharmaceutical company Pfizer Inc. a patent for its pneumonia … Continue reading

Posted in Evergreening, Indian Patent Law, Patent, Patent Opposition, Uncategorized, Vaccines | Leave a comment